Insulin Resistance 胰島素阻抗

COND-insulin-resistance

5

interventions reviewed

B

top tier

2

counter-evidence

B Preliminary 1

Published with Warning ⚠️ 中度市場風險

C Weak 2

鉻（三價鉻）

Published ⚠️ 中度市場風險

Nicotinamide Mononucleotide (NMN)

菸鹼醯胺單核苷酸 (NMN)

Published with Warning 🚨 高市場風險

D Counter-evidence 2

Bitter Melon Peptide (mcIRBP-19 / MAP30)

苦瓜胜肽（山苦瓜胜肽 / mcIRBP-19）

Disputed ⚠️ 中度市場風險

Nicotinamide Riboside

菸鹼醯胺核糖

Taiwan Regulatory Restriction ✨ 低市場風險